{
  "attach_pages": "3",
  "attach_size": "778",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201908011341903828_1.pdf?1564658425000.pdf",
  "company_code": "80385468",
  "eitime": "2019-08-01 11:11:48",
  "extend": {},
  "info_code": "AP201908011341903828",
  "language": "0",
  "notice_date": "2017-10-26 00:00:00",
  "notice_title": "输液产品结构优化促毛利率提升，川宁满产和转型研发创新值得期待",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "researcher": "唐爱金,李安飞",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "科伦药业",
      "short_name_ch": "科伦药业",
      "short_name_cht": "科倫藥業",
      "short_name_en": "KELUN PHARMA",
      "stock": "002422"
    }
  ],
  "short_name": "科伦药业",
  "source_sample_name": "广州广证恒生市场研究"
}